enGene Therapeutics Inc 8-K/A, filed Oct 2, 2025
enGene Therapeutics Inc. (ENGN)
About this 8-K/A
enGene Therapeutics Inc filed this 8-K/A on October 2, 2025, reporting on events of July 7, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 8, 2025, enGene Holdings Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that, on and effective as of July 8, 2025, the Board of Directors of the Company (the “Board”) appointed Messrs. Philip Astley-Sparke and Michael Heffernan to the Board as directors. At the time of the filing of the Original Form 8-K, committee assignments for these directors had not been determined.
The Company is filing this Amendment to the Original Form 8-K to disclose that, on and effective as of October 2, 2025, the Board appointed Mr. Astley-Sparke to serve as a member of each of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, and appointed Mr. Heffernan to serve as a member of each of the Audit Committee and the Compensation Committee of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ENGENE HOLDINGS INC. |
|
|
|
|
Date: |
October 2, 2025 |
By: |
/s/ Ronald H.W. Cooper |
|
|
|
Name: Ronald H.W. Cooper |